You need to enable JavaScript to run this app.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
GvHD Types
Chronic graft-versus-host disease
Acute graft-versus-host disease
Graft-versus-host disease
View all Types
Anna Bartus
Anna Bartus
Types
Acute graft-versus-host disease
Chronic graft-versus-host disease
Cutaneous aGvHD
Cutaneous cGvHD
Fascia-associated cGvHD
GI aGvHD
Lower GI cGvHD
Ocular cGvHD
Oral cGvHD
Pulmonary cGvHD
Steroid-refractory GvHD
Upper GI cGvHD
Interventions
Abatacept
Alemtuzumab
Allo-HSCT
Allo-NKT
Antithymocyte globulin
Azacitidine
Basiliximab
Bortezomib
Busulfan
Cyclophosphamide
Cyclosporin A
Daclizumab
Etanercept
Extracorporeal photopheresis
Fecal microbiota transplant
Fludarabine
Ibrutinib
Infliximab
Ixazomib
KD025
Mesenchymal stromal cells
Methotrexate
Methylprednisolone
Microbiota therapy
Mycophenolate mofetil
Prednisone
Rituximab
Ruxolitinib
Sirolimus
Tacrolimus
Treosulfan
Vedolizumab
α1-Antitrypsin
Congresses
ASH 2018
ASTCT and CIBMTR TCT Meeting 2019
EBMT 2018
EBMT 2019
EBMT GvHD Summit 2019
EHA 2018
EHA 2019
IACH 2018
Trials
GRAVITAS-301
REACH1
REACH2
All
|
87 Articles
|
12 Videos
|
0 Podcasts